Question-and-Answer Session
Operator
(Operator Instructions) And your first question comes from the line of Adam Green of JP Morgan. Please proceed sir
Adam Green- JP Morgan
Thanks, good morning, Pat you mentioned some of the potential first of file opportunities for 09 and beyond, but could you highlight, some of the potential launches that we might see over the next 12 to 24 months the first to file, and also in the fourth quarter, will you be the only player out there so we assume that offer the generic on that target as well?
Pat LePore
Thanks Adam, I ask Paul Campanelli who runs our generic business to respond.
Paul Campanelli
With respect to unauthorized generic, again that was a settlement between Par and GSK, we have a partner in Spectrum as you know, we anticipate a single competitor on one dosage form. We are holding approximately three or four dosage strengths, so we are feeling fairly secure that we will see only one competitor on these single dosage forms, at least until the compound pack expires.
Regarding 2009 potential first to file launches, again at our analysts meeting back in September, we had provided a list of targets in terms of successes, but several products that we indicated back in September of 2007 included [inaudible].
Adam Green-JP Morgan
In fact, this is a follow up, you mention some of the products that have send decline like amoxicillin and fluticasone and a lot of the products that you didn’t mention are also seeing fairly sizeable decline like cefaloxin and was there some type of products or portfolio rationalization over the last several months that would cause that precipitous decline?
Pat LePore
We have seen that decline, and I will tell at this stage of the game though, we are seeing competition on all of our products, we are seeing a lot of pricing pressures on majority of our products, with the exception of [inaudible] at this stage of the game.
Adam Green-JP Morgan
Okay, thank you.
Operator
Your next question comes from the line of David Glick of Buckingham Research, please proceed sir
David Glick - Buckingham Research
Yes, thanks, Patrick I know you mentioned that you will try to get a more of a clear look into the guidance of the first quarter, but can you give us an overall sense of what you’re expecting in terms of further generic price erosion, and what the rates then for this year, and then maybe commentary on you know at least the first quarter where SG&A and R&D might be.
- To read the full transcript on Seeking Alpha, click here »
